Lisa Astor

At a median follow-up of almost two years, 88.5% of patients remained on study treatment.

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Some women with hormone-driven early breast cancer can skip chemotherapy after surgery.

Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.